NADPH oxidase gene therapy (Genethon)

N/A

Report date: 2026/01/20 17:48:44

Base Information

Drug NameNADPH oxidase gene therapy (Genethon)
Drug Alias NameNADPH氧化酶基因治疗 - GenethonChronic granulomatous disease gene therapy, G1XCGD transduced CD34+ cellsLentiviral vector transduced CD34+ cellsg1xcgdOTL-102
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionNADPH oxidase 1 stimulantsGene transference
TargetsNADPH oxidase 1
Therapy Area/IndicationsGranulomatous Disease, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenethon
China Registration ClassN/A

Develop Information

Active CompaniesGenethonUniversity Of California, Los Angeles
Inactive CompaniesN/A
Active IndicationsGranulomatous Disease, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A